Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial PharmaphorumRoche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.OncologyRead full story pharminent July 2, 2026 (Last updated: July 2, 2026) Pharmaphorum Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib. Oncology Read full story Post navigation Previous: Insilico Medicine, Takeda partner on AI-driven drug discoveryNext: AZ forges ever-closer ties with China’s CSPC Pharma Related Stories Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026 Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026 Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026
